



I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on
Sept 16, 2002
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C.
By: Shane Brooks

#48/29
Atty Docket No: 402E-978316US 10/9/02
Client Ref: P0233C6
M

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Phillip W. Berman; Laurence A. Lasky

Application No.: 08/459,141

Filed: 6/2/1995

For: **Immunogenic Composition Based on a Truncated Derivative of a Membrane Bound Protein And Process For Making It**

Examiner: Winkler, U.

Art Unit: 1648

RECEIVED

SEP 27 2002

TECH CENTER 1600/2900

RESPONSE

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated March 15, 2002, Applicants respectfully request reconsideration of the above-identified application in view of the following amendments and remarks. The following document(s) is/are enclosed herewith:

- 1) A petition to extend the period of response for 3 months.
- Please amend the specification and/or claims as follows.

In the Specification.

Please delete the paragraph beginning at page 6, line 4 and substitute therefore the following new paragraph(s):

As used herein, the term "recombinant" refers to cells which have been transfected with vectors constructed using recombinant DNA technology and thus transformed with the capability of producing the polypeptide hereof. "Functional association" is meant being bound to the membrane, typically by projecting to both sides of the membrane, in such manner as to expose antigenic determinants folded in a native conformation recognizable by antibody elicited against the native pathogen. "Membrane-bound" in reference to polypeptides hereof refers to a class of polypeptides ordinarily produced in eukaryotic cells and characterized by having a signal sequence

J